Literature DB >> 25168833

The treatment of idiopathic focal segmental glomerulosclerosis in adults.

Jonathan Hogan1, Jai Radhakrishnan2.   

Abstract

Focal segmental glomerulosclerosis (FSGS) is the histologic end point of many disease processes that affect the kidney. Clinically, adults with FSGS present with proteinuria that may be accompanied by the nephrotic syndrome. Once identifiable (secondary) causes are excluded, the diagnosis of idiopathic FSGS, a challenging glomerular disease to understand and manage, is made. On the basis of mostly retrospective data, first-line treatment for idiopathic FSGS patients with nephrotic-range proteinuria is a prolonged course of corticosteroids. However, steroid resistance is common and portends an increased risk of long-term decline in kidney function and end-stage kidney disease in these patients compared with responders. Multiple other immunosuppression regimens have been used in steroid-resistant FSGS, some of which have been studied in randomized controlled trials. Here, we review the data on the treatment for idiopathic FSGS in adults.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Focal segmental glomerulosclerosis

Mesh:

Substances:

Year:  2014        PMID: 25168833     DOI: 10.1053/j.ackd.2014.03.016

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  7 in total

1.  Rethinking First-Line Immunosuppression for Idiopathic FSGS.

Authors:  Jordana B Cohen; Jonathan J Hogan
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-16       Impact factor: 8.237

Review 2.  Focal Segmental Glomerulosclerosis.

Authors:  Avi Z Rosenberg; Jeffrey B Kopp
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-27       Impact factor: 8.237

3.  Emerging drugs for treatment of focal segmental glomerulosclerosis.

Authors:  Howard Trachtman
Journal:  Expert Opin Emerg Drugs       Date:  2020-08-12       Impact factor: 4.191

4.  Pharmacological and genetic inhibition of downstream targets of p38 MAPK in experimental nephrotic syndrome.

Authors:  Xiaojing Nie; Melinda A Chanley; Ruma Pengal; David B Thomas; Shipra Agrawal; William E Smoyer
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-29

5.  Albumin-based nanoparticles as methylprednisolone carriers for targeted delivery towards the neonatal Fc receptor in glomerular podocytes.

Authors:  Lin Wu; Mingyu Chen; Huijuan Mao; Ningning Wang; Bo Zhang; Xiufen Zhao; Jun Qian; Changying Xing
Journal:  Int J Mol Med       Date:  2017-02-21       Impact factor: 4.101

6.  FAM40A alters the cytoskeleton of podocytes in familial focal and segmental glomerulosclerosis by regulating F-actin and nephrin.

Authors:  Zhou Chen; Yinghui Zhang; Xuezhi Zhao
Journal:  Arch Med Sci       Date:  2018-02-02       Impact factor: 3.318

7.  The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network.

Authors:  Jonathan P Troost; Anne Waldo; Noelle E Carlozzi; Shannon Murphy; Frank Modersitzki; Howard Trachtman; Patrick H Nachman; Kimberly J Reidy; David T Selewski; Emily G Herreshoff; Tarak Srivastava; Keisha L Gibson; Vimal K Derebail; Jen Jar Lin; Sangeeta Hingorani; Alessia Fornoni; Fernando C Fervenza; Kamalanathan Sambandam; Ambarish M Athavale; Jeffrey B Kopp; Heather N Reich; Sharon G Adler; Larry A Greenbaum; Katherine M Dell; Gerald Appel; Chia-Shi Wang; John Sedor; Frederick J Kaskel; Richard A Lafayette; Meredith A Atkinson; John C Lieske; Christine B Sethna; Matthias Kretzler; Michelle A Hladunewich; Kevin V Lemley; Elizabeth Brown; Kevin E Meyers; Crystal A Gadegbeku; Lawrence B Holzman; Jonathan Ashley Jefferson; Katherine R Tuttle; Pamela Singer; Marie C Hogan; Daniel C Cattran; Laura Barisoni; Debbie S Gipson
Journal:  Clin Kidney J       Date:  2019-08-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.